Stockscreener 앱 받기
0.8387
3.55%
-0.0309
시간 외 거래:
.84
0.0013
+0.16%
전일 마감가:
$0.8696
열려 있는:
$0.8561
하루 거래량:
32,020
Relative Volume:
0.21
시가총액:
$84.33M
수익:
-
순이익/손실:
$-30.15M
주가수익비율:
-0.9216
EPS:
-0.91
순현금흐름:
$-31.63M
1주 성능:
-10.79%
1개월 성능:
+39.99%
6개월 성능:
-62.05%
1년 성능:
-54.66%
1일 변동 폭
$0.8353
$0.8979
1주일 범위
$0.80
$0.9401
52주 변동 폭
$0.55
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
CNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.8387 | 84.33M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus
Context Therapeutics appoints new interim CMO - Investing.com
Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire
Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN
What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World
Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World
Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World
Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World
Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India
Context Therapeutics (CNTX) Presents Promising Data on CT-95 at AACR 2025 | CNTX Stock News - GuruFocus
Context Therapeutics reports progress in cancer treatment - Investing.com Australia
Context Therapeutics Inc. Announces Preclinical Data Supporting Unique Binding Mechanism of CT-95 and Progress in Phase 1 Clinical Trial - Nasdaq
Context Therapeutics Presents Preclinical and Translational - GlobeNewswire
Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan
Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - Nasdaq
Bet on These 5 Top-Ranked Stocks With Rising P/E - NewsBreak: Local News & Alerts
William Blair starts Context Therapeutics stock with Outperform By Investing.com - Investing.com Canada
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Optimistic Outlook | CNTX Stock News - GuruFocus
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - ADVFN
Context Therapeutics Reports Full Year 2024 Operating and Financial Results - ADVFN
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
D. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
Context Swoons on CT-95 First Dose - Baystreet.ca
Context Therapeutics Begins Phase 1 Trial for CT-95 - TipRanks
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - GlobeNewswire
Breakthrough Cancer Treatment Launches Trial: Targets 30% of All Cancer Types - Stock Titan
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Yahoo Finance
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Yahoo Finance
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo
Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Context Therapeutics Unveils Packed Schedule: 4 Elite Healthcare Conferences Coming Up - Stock Titan
Context Therapeutics: 2024 Financial and Strategic Highlights - TipRanks
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Brokerages - Defense World
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView
Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 - Stock Titan
JMP maintains $4 target on Context Therapeutics stock By Investing.com - Investing.com UK
What is HC Wainwright’s Forecast for CNTX Q3 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Yahoo Finance
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN
Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):